NCT00528372[Secondary Source ID] - Search Results

Your saved search

Your RSS Feed

Year	Number of Results
2016	2
2024	1
2025	0

Page 1

Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.

Natale P, Tunnicliffe DJ, Toyama T, Palmer SC, Saglimbene VM, Ruospo M, Gargano L, Stallone G, Gesualdo L, Strippoli GF. Natale P, et al. Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2. Cochrane Database Syst Rev. 2024. PMID: 38770818 Free PMC article.

The effect of dapagliflozin on renal function in patients with type 2 diabetes.

Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L. Kohan DE, et al. J Nephrol. 2016 Jun;29(3):391-400. doi: 10.1007/s40620-016-0261-1. Epub 2016 Feb 19. J Nephrol. 2016. PMID: 26894924 Clinical Trial.

Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.

Mellander A, Billger M, Johnsson E, Träff AK, Yoshida S, Johnsson K. Mellander A, et al. Clin Drug Investig. 2016 Nov;36(11):925-933. doi: 10.1007/s40261-016-0438-3. Clin Drug Investig. 2016. PMID: 27461213

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year